ASX:CSLBiotechs
A Look At CSL (ASX:CSL) Valuation After Clazakizumab Deal And Recent Earnings Pressure
CSL (ASX:CSL) has come into focus after out licensing its IL 6 antibody clazakizumab to Eli Lilly, securing A$100 million up front, along with future milestones and royalties tied to Lilly led development.
See our latest analysis for CSL.
That clazakizumab deal lands at a time when CSL’s share price has been under pressure, with a 30 day share price return showing an 18.55% decline, a 90 day share price return showing a 21.22% decline and a 1 year total shareholder return showing a 42.56%...